What is the appropriate treatment for a recurrent Crohn disease flare-up?

Treatment of Recurrent Crohn's Disease Flare-Up

For a recurrent Crohn's disease flare-up, initiate oral corticosteroids (prednisolone 40 mg daily) for moderate to severe disease, or high-dose mesalazine (4 g/daily) for mild ileocolonic disease, while simultaneously starting or optimizing maintenance therapy with azathioprine or mercaptopurine to prevent future relapses. 1

Initial Assessment and Treatment Selection

Before initiating treatment, assess three critical factors that determine your approach:

• Disease location: ileal, ileocolonic, or colonic
• Disease pattern: inflammatory, stricturing, or fistulating
• Disease severity: mild, moderate, or severe activity

Rule out alternative explanations for symptoms including bacterial overgrowth, bile salt malabsorption, fibrotic strictures, or infectious complications before attributing symptoms to active inflammation 1.

Induction Therapy Based on Severity

Mild Ileocolonic Disease

Start with high-dose mesalazine 4 g/daily as initial therapy 1. This approach is supported by grade A evidence and avoids corticosteroid exposure in patients who may respond to aminosalicylates alone.

Moderate to Severe Disease

Use oral prednisolone 40 mg daily, tapering gradually over 8 weeks according to patient response 1. Rapid steroid reduction increases early relapse risk, so resist pressure to taper faster than this timeframe.

For isolated ileo-caecal disease with moderate activity, budesonide 9 mg daily is an alternative, though marginally less effective than prednisolone 1.

Severe Disease Requiring Hospitalization

Administer intravenous steroids (hydrocortisone 400 mg/day or methylprednisolone 60 mg/day) with concomitant IV metronidazole, as distinguishing active disease from septic complications can be difficult 1. Monitor vital signs four times daily, maintain stool charts, and check inflammatory markers every 24-48 hours 1.

Critical: Initiating Maintenance Therapy

This is where most clinicians fail in managing recurrent flares. A recurrent flare signals that your patient needs maintenance immunosuppression, not just repeated courses of steroids.

First-Line Maintenance: Thiopurines

Start azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 0.75-1.5 mg/kg/day as the steroid dose is reduced 1, 2. These agents are particularly indicated for:

• Patients with extended disease at risk for relapse
• Those with adverse prognostic factors (early age of onset, perianal disease, glucocorticosteroid use at presentation, severe presentations) 2
• Steroid-dependent patients who relapse when steroids are reduced below 20 mg/day or within 6 weeks of stopping 1

Monitor FBC within 4 weeks of starting therapy and every 6-12 weeks thereafter to detect neutropenia 1.

Second-Line Maintenance: Methotrexate

Use methotrexate 15-25 mg IM weekly for patients who 1, 2:

• Are intolerant of azathioprine/mercaptopurine
• Have contraindications to thiopurines
• Have failed thiopurine therapy

Prescribe daily folic acid to minimize adverse events 3.

Biologic Therapy for Refractory Disease

When to Escalate to Biologics

Consider biologics when patients have 2, 4:

• Severe active disease not responding to conventional therapy
• Steroid-refractory disease (active despite prednisolone >20 mg/day for >2 weeks)
• Steroid-dependent disease despite adequate immunomodulator therapy
• Contraindications or intolerance to conventional therapy

Biologic Selection

Anti-TNF agents (infliximab 5 mg/kg or adalimumab) remain first-line biologics with the most robust evidence 2, 4, 5. For anti-TNF failures:

• After primary non-response to infliximab: Use ustekinumab (preferred) or vedolizumab 5
• After secondary loss of response to infliximab: Switch to adalimumab or ustekinumab 5
• After adalimumab failure: Consider infliximab as indirect evidence supports this switch 5

Risankizumab (IL-23 inhibitor) shows superiority over ustekinumab in anti-TNF experienced patients per the SEQUENCE trial 6.

Upadacitinib (JAK-1 inhibitor) is approved specifically for patients who have failed or are intolerant to anti-TNF agents 6.

Common Pitfalls to Avoid

1. Repeated steroid courses without maintenance therapy: This is the most common error. Steroids do not maintain remission 1, 7. After the second flare requiring steroids, immunomodulators are mandatory.

2. Using mesalazine alone for maintenance after steroid-induced remission: Mesalazine has limited benefit and is ineffective at doses <2 g/day or for those who needed steroids to induce remission 1. It should not be relied upon as sole maintenance therapy in recurrent disease.

3. Delaying immunomodulator initiation: Start azathioprine/mercaptopurine during the steroid taper, not after completing it. The onset of action takes 2-3 months 3.

4. Inadequate steroid taper duration: Tapering faster than 8 weeks increases early relapse risk 1.

5. Missing surgical indications: For localized ileocaecal disease with obstructive symptoms but minimal inflammation, surgery may be preferable to escalating medical therapy 8.

Smoking Cessation is Non-Negotiable

All smokers must be strongly advised to stop with active support (counseling, nicotine patches, substitutes) 1, 8. Smoking cessation is probably the most important factor in maintaining remission and reducing surgical risk.

Monitoring During Treatment

• Check inflammatory markers (CRP, ESR) and albumin every 24-48 hours during severe flares 1
• Assess clinical response to IV steroids within 72 hours; if no improvement, intensify therapy 9
• Monitor FBC regularly on thiopurines (within 4 weeks, then every 6-12 weeks) 1
• Consider ileocolonoscopy 6-9 months post-remission to assess mucosal healing and guide treatment adaptation 3